Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
01:00pm, Wednesday, 22'nd Mar 2023
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
Sanofi becomes latest to cut insulin prices, joins Novo Nordisk, Eli Lilly
10:25am, Friday, 17'th Mar 2023
Yahoo Finance's Anjalee Khemlani joins the Live show to report that Sanofi has become the latest major drug company to slash insulin prices, capping the cost at $35.
2 Top Healthcare Stocks to Buy for the Long Haul
10:15am, Friday, 17'th Mar 2023
Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk
05:45pm, Thursday, 16'th Mar 2023
The French company will cap the monthly cost of insulin at $35, after Novo Nordisk and Eli Lilly also announced major price cuts earlier this month.
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk
04:45pm, Thursday, 16'th Mar 2023
The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
12:14pm, Wednesday, 15'th Mar 2023
Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.
Novo Nordisk to slash US prices of insulin pens and vials by up to 75% for people with diabetes
12:06pm, Tuesday, 14'th Mar 2023
Novo Nordisk (NYSE:NVO) A/S is set to cut the US list prices for several insulin products by up to 75% for people struggling with diabetes, following similiar moves by Eli Lilly earlier this month. Th
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
11:00am, Tuesday, 14'th Mar 2023
Novo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
Novo Nordisk to lower prices of some insulins, following similar move by Lilly
08:45am, Tuesday, 14'th Mar 2023
Novo Nordisk DK:NOVO.B NVO said that it is lowering the prices of several insulin products by up to 75% starting in 2024. The company's U.S.-listed shares were up about 1.0% in premarket trading on Tu
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
09:11am, Thursday, 09'th Mar 2023
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sa
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
07:12am, Tuesday, 07'th Mar 2023
Former WeightWatchers is entering clinical weight management. WW stock surged.
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains Steam
08:59am, Saturday, 04'th Mar 2023
Arista Networks, which keeps popping up on lists of top AI stocks, leads this weekend's watch list of 5 stocks near buy points. The post AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Ral
4 Low-Beta Stocks to Buy to Combat the Volatile Market
09:02am, Thursday, 02'nd Mar 2023
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Employers Holdings (EIG), The Hershey (HSY), Lamb Weston (LW) and Novo Nordisk (NVO) are poised to gain.
Novo Nordisk laying off 86 workers as part of lab shutdown in Seattle
06:46pm, Wednesday, 01'st Mar 2023
Danish multinational biopharma company Novo Nordisk is laying off 86 employees in Seattle, according to a new filing with the Washington state Employment Security Department.
What Makes Novo Nordisk (NVO) a New Strong Buy Stock
01:32pm, Monday, 20'th Feb 2023
Novo Nordisk (NVO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
